Related Experiment Video

Updated: Jul 30, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.9K

PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment

Robert B Kargbo1

  • 1Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.

ACS Medicinal Chemistry Letters
|May 17, 2023
PubMed

Insights

New PROTAC compounds effectively degrade anti-apoptotic BCL-2 proteins, offering potential cancer and autoimmune disease treatments. These targeted therapies show promise for enhanced drug development.

Area of Science:

  • Oncology and Immunology
  • Drug Discovery and Development

Background:

  • Anti-apoptotic BCL-2 family proteins (BCL-2, BCL-XL, MCL-1) are validated cancer targets, with venetoclax approved in 2016.
  • Development of novel analogs with improved pharmacokinetic and pharmacodynamic properties is an active research area.

Discussion:

  • This Patent Highlight introduces Proteolysis-Targeting Chimeras (PROTACs) designed for potent and selective degradation of BCL-2.
  • PROTACs offer a mechanism to eliminate target proteins, distinct from traditional inhibition.

Key Insights:

  • The featured PROTAC compounds demonstrate significant BCL-2 degradation capabilities.
  • These compounds exhibit selectivity, minimizing off-target effects.

Outlook:

  • Potential therapeutic applications include cancer, autoimmune disorders, and immune system diseases.
  • Further research into PROTAC technology may yield next-generation therapeutics with enhanced efficacy and safety profiles.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
587